How to buy NeuroMetrix stock - 09 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy NeuroMetrix stock

Own NeuroMetrix stock in just a few minutes.

Posted

Fact checked

NeuroMetrix, Inc is a medical instruments & supplies business based in the US. NeuroMetrix shares (NURO) are listed on the NASDAQ and all prices are listed in US Dollars. NeuroMetrix employs 20 staff and has a trailing 12-month revenue of around USD$7.4 million.

How to buy shares in NeuroMetrix

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for NeuroMetrix. Find the stock by name or ticker symbol: NURO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until NeuroMetrix reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of NeuroMetrix, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of NeuroMetrix. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

NeuroMetrix share price

Use our graph to track the performance of NURO stocks over time.

NeuroMetrix shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$0.812 - USD$5.78
50-day moving average USD$4.0765
200-day moving average USD$2.529
Wall St. target priceUSD$50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.395

Buy NeuroMetrix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NeuroMetrix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NeuroMetrix financials

Revenue TTM USD$7.4 million
Gross profit TTM USD$5.2 million
Return on assets TTM -14.65%
Return on equity TTM -53.8%
Profit margin -28.36%
Book value $1.383
Market capitalisation USD$13.4 million

TTM: trailing 12 months

Shorting NeuroMetrix shares

There are currently 14,833 NeuroMetrix shares held short by investors – that's known as NeuroMetrix's "short interest". This figure is 42.7% down from 25,890 last month.

There are a few different ways that this level of interest in shorting NeuroMetrix shares can be evaluated.

NeuroMetrix's "short interest ratio" (SIR)

NeuroMetrix's "short interest ratio" (SIR) is the quantity of NeuroMetrix shares currently shorted divided by the average quantity of NeuroMetrix shares traded daily (recently around 494433.33333333). NeuroMetrix's SIR currently stands at 0.03. In other words for every 100,000 NeuroMetrix shares traded daily on the market, roughly 30 shares are currently held short.

However NeuroMetrix's short interest can also be evaluated against the total number of NeuroMetrix shares, or, against the total number of tradable NeuroMetrix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NeuroMetrix's short interest could be expressed as 0% of the outstanding shares (for every 100,000 NeuroMetrix shares in existence, roughly 0 shares are currently held short) or 0.0039% of the tradable shares (for every 100,000 tradable NeuroMetrix shares, roughly 4 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NeuroMetrix.

Find out more about how you can short NeuroMetrix stock.

NeuroMetrix share dividends

We're not expecting NeuroMetrix to pay a dividend over the next 12 months.

Have NeuroMetrix's shares ever split?

NeuroMetrix's shares were split on a 1:10 basis on 19 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeuroMetrix shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for NeuroMetrix shares which in turn could have impacted NeuroMetrix's share price.

NeuroMetrix share price volatility

Over the last 12 months, NeuroMetrix's shares have ranged in value from as little as $0.812 up to $5.78. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeuroMetrix's is 2.9685. This would suggest that NeuroMetrix's shares are significantly more volatile than the average for this exchange and represent a higher risk.

NeuroMetrix overview

NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site